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1. Introduction 
Idiopathic polymyositis is a chronic inflammatory systemic disease with preponderant 
infestation of the musculature. Dermatomyositis also involves skin participation (Conrad et 
al., 2001c; Kalovidouris, 1992; Mimori, 1996). Idiopathic, secondary and paraneoplastic 
forms of the disease can also be observed. The first report about myositis was given in 1863 
by Wagner (Wagner, 1863). Also Unverricht (Unverricht, 1887) reported in 1887 about a case 
about Myositis, and introduced the concept of dermatomyositis in 1891.  
In addition, distinct forms of interstitial myositis, marked by an appearing from foci of 
inflammation in the muscular interstitium and causative organism conditioned Myositis can 
be observed. The cause-conditioned myositis can be driven by Toxoplasma gondii or 
Trichinella spiralis infections (parasitcal myositis) and by Clostridium perfringens or 
staphylococcal infections (bacterial myositis).  
Although myositis is a rather rare disease with an annual incidence of 1:100 000- 280.000 
inhabitants, this illness belonging to the collagenosis group is, on account of the therapeutic 
consequences (Glucocorticoides and Immunsuppressiva) and the clinically often observed 
muscle discomfort, of considerable differential-diagnostic meaning.  
Women are more frequently affected than men, the relation being about 2:1. The age 
distribution is marked by two maxima, for the juvenile form between the 5th and 15th year 
and the adult form beyond the 5th decade (2004).  
The aetiology is unknown. A toxic infectious genesis is discussed among other causes and, 
in particular with juvenile dermatomyositis, Coxsackie viruses are considered as the cause, 
an allergic genesis on account of the appearance of a dermatomyositis after taking of 
antibiotics or sulphonamides and an immunologic genesis on account of the proof of 
autoantibodies. The illnesses relation with cancer could originate on the base of 
immunological cross reactions between tumour antigens and skin-muscle antigens or by a 
myotoxical substance secreted by the tumour tissue (Burmester et al., 2001). A causal 
connection between malignant and autoimmune disease could be seen in the disappearance 
or the decline of myositis symptoms after successful treatment of the tumour (in more than 
10 % of the observed cases). Various studies show a raised appearance of cancer of the most 
different kind with patients with diagnosed Myositis (Manchul et al., 1985; Maoz et al., 1998; 
Zantos et al., 1994). 
2. Serological aspects 
Myositis can be serologically diagnosed by autoreactivity against a distinct pattern of 
autoantibodies. Different subsets of autoantibodies targeting distinct groups of antigens 
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facilitate a differential diagnosis of the subforms of myositis and discrimination to other 
autoimmune diseases. Many myositis specific antibodies (MSA) and myositis associated 
antibodies (MAA) have been found and described, as shown in Table 1 and Table 2. 
 
Antibody Nature of antigen 
prevalence 
[ % of IIM] 
Clinical 
relevance 
Myositis specific    
a-Jo1 Histidyl-tRNA synthetase(50 kDa) 30 PM 18-46 
antisynthetase 
syndrom 
a-PL7 Threonyl-tRNA synthetase(80 kDa) <5  
a-PL12 Alanyl-tRNA synthetase(110 kDa) <5  
a-OJ 
Isoleucyl-tRNA 
synthetase(multienzyme) 
<5  
a-EJ Glycyl-tRNA synthetase(75 kDa) <5  
a-Ks Asparaginyl-tRNA-Synthetase <1 
Intersititial lung 
manifestation 
a-YRS Tyrosyl-tRNA Synthetase <1  
a-Zo Phenylalanyl tRNA synthetase <1 
Nonspec 
interstitial lung 
disesae 
a-SRP Signal Recognition particle <5 severe PM 
a-Mi-2 218 kDa DNA helicase 15-31 DM 
a-KJ Translation factor <1 PM 
a-Fer Elongation factor 1 α (48 kDa) <1 Nodular myositis 
a-Mas  <1  
a-MDA 5 
a-CADM140 
melanoma differentiation-associ-
ated gene 5 
~ 25% in DM 
Interstital lung 
disease with 
amyopathic DM 
a-TIF1-gamma 
transcriptional intermediary factor 
1-gamma 
~ 15% in DM 
DM and malig-
nancy 
a-p100/p200 unknown unknown 
Necrotising 
myopathy  w/o 
other specificities 
Table 1. Myositis specific antigens (MSA) targeted by the immune system in myositis.  
3. Synthetases 
T-RNA-synthetases are the most prominent group of autoantigens targeted in myositis. The 
antibodies here target a group of proteins all having a similar function in the cell: the 
binding of an aminoacid to its determined tRNA molecule to form the aminoacyl tRNA 
which afterwards is used by a ribosome in the protein biosynthesis. There are two classes of 
tRNA synthetases, class 1 and class 2. Aminoacyl tRNA synthetase molecules are 
differentiated via the different ways of tRNA binding and characteristically structural 
motives. Class 1 tRNA synthetases have two highly conserved structural motives while  
class 2 synthetases have three characteristical motives.  
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Myositis 
associated 
   
a-Ku DNA PK regulating subunit 5-25 PM SSc overlap 
a-PmScl 
Nuclear protein complex 110-20 
kDa
24 PM SSc overlap 
a-U2RNP 
U2 small RNP( mRNA splicing 
factor)
<5 PM SSc overlap 
a-DNA PKcs DNA PK katalytic subunit <5 
PM, PM-SSC 
overlap 
a-Ro52 
(RBCC) tripartite motif protein 
ubiquitin-ligase 
5-10 
antisynthetase 
syndrom 
PM/DM 
a-U1RNP 
U1 small RNP( mRNA splicing 
factor)
4-17 PM 100% MCTD 
Anti Calpastatin Calpain Inhibitor 24 
Often ass.with 
RA 
Anti Annexin 
Ca dep. Phospholipid binding 
protein
10 - 
Table 2. Myositis associated antigens (MAA) targeted by the immune system in myositis.  
3.1 Jo-1 histidyl-tRNA-synthetase 
Antibodies against the Jo-1 antigen are the most frequent antibodies to be found in 
Polymyositis/Dermatomyositis (PM/DM). They occur with a prevalence of 20-30%, 
independent of ethnic and geographical population (Nishikai and Reichlin, 1980). The 
characterisation of Jo-1 as histidyl-tRNA-synthetase was achieved using 
immunoprecipitation of tRNAHIS together with a 50 kDa protein by Hirkata et al. in 1992 
(Hirakata et al., 1992). Patients with serological reactivity against Jo-1 often suffer from 
Myositis, Polyarthritis, mechanics hands and Raynaud´s phenomenon (Nishikai and 
Reichlin, 1980). Like mentioned, tRNA-synthetases can be classed into two subgroups, class 
1 and class 2 synthetases. Most synthetases targeted by the immune system in myositis 
belong two the class 2 group of enzymes. The epitope often is the synthetase enzyme itself, 
not the tRNA. Therefore myositis with reactivities against Jo-1, PL12, PL7, EJ and OJ is often 
called the synthetase syndrome. Figure 1 shows the three dimensional structure of the Jo-1 
Antigen in a monomeric form (Guex and Peitsch, 1997; Peitsch et al., 2000; Schwede et al., 
2003; Aberg et al., 1997), figure 2 shows the tetrameric form as the protein occurs in the cell. 
Structures have been taken from the protein databank (www.pdb.org). The figure shows 
how the four subunits interdigitate to form an H-like structure. For visualisation the 
subunits are shown in different colours. Jo-1 can be easily produced recombinantly using 
the Baculovirus expression system (Hentschel et al., 2002; Schulte-Pelkum, 2005). 
3.2 PL7 threonyl-tRNA-synthetase 
Anti PL7 autoantibodies, also called TRS-antibodies, bind the tRNA for threonine and an 80 
kDa protein of the threonyl-tRNA-synthetase complex. In indirect immunofluorescence 
microscopy(IIF) a diffuse fine granular cytoplasmic fluorescence can be seen (Conrad et al., 
2001a). The clinical manifestations of patients with anti-TRS- antibodies are similar to the 
clinical manifestations of patients with anti Jo-1 antibodies, but the prevalence of these 
reactivities is much lower (2-5 %). 
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Fig. 1. Histidyl tRNA Ligase monomer, according Aberg et al. (Aberg et al., 1997). 
 
 
Fig. 2. Histidyl tRNA Ligase tetramer (Aberg et al., 1997). 
3.3 PL12 alanyl-tRNA synthetase 
Anti-Pl 12-antibodies react with a 110 kDa protein, the alanyl-tRNA synthetase. Sera having 
this reactivity also contain antibodies directly binding the alanyl aminoacyl tRNA. Next to 
the relative low prevalence of less than 5 % in myositis, these antibodies are also found in 
interstitial lung diseases without myositis manifestation (Hirakata et al., 1995).  
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3.4 EJ glycyl-tRNA synthetase 
Anti-EJ-Antibodies bind a 75 kDa-protein of glycyl-tRNA synthetase together with four of 
the glycyl-tRNAs. This parameter is also of a low frequence. Of interest may be, that anti-EJ 
antibodies can, like anti Jo-1 antibodies precede the clinical symptoms of myositis (Targoff, 
2000). Anti-EJ-antibodies have a prevalence of less than 5 % in myositis patients.  
3.5 OJ- isoleucyl-tRNA synthetase 
Anti OJ antibodies have Isoleucyl-tRNA synthetases as a main target, but also bind to other 
synthetases. The main epitope of anti OJ antibodies seems to be directed against a 
multienzyme complex, containing aminoacyl-tRNA synthetase activity for up to nine 
different amino acid systems. Anti OJ-antibodies have a prevalence of less than 5 % in 
myositis 
3.6 KS- asparaginyl tRNA-synthetase 
Anti KS antibodies bind Asparaginyl tRNA-synthetase. An anti KS-reactivity is not a clear 
marker for myositis, the majority of patients showing anti KS-reactivity suffers from 
interstitial lung disease and not from myositis (Hirakata et al., 1999). 
3.7 ZO phenylalanyl tRNA synthetase 
First described by Betterige (Betteridge et al., 2007) in a patient showing clinical symptoms 
of an antisynthetase syndrome, but showing no positive serological reaction to the 
previously identified anti-synthetase autoantibodies. Up to now only one patient has been 
found with this reactivity. 
4. Mi2 antigen: nucleosome remodeling deacetylase 
Anti Mi2 Antibodies are well known markers for dermatomyositis with an apparent 
prevalence of 15-30 % in patients with DM (Conrad et al., 2001b), although the biological 
function of the Mi2 protein in the cell remained elusive for a long time (Targoff, 2000). Anti 
Mi2 Antibodies can be found in ca. 20 % of patients suffering from the adult form of 
dermatomyositis. The function of this protein seems to be to catalyze the unwinding of 
chromatin structures in chromosomal DNA. The protein possesses one DNA binding 
domain and one helicase domain (Targoff, 2000; Woodage et al., 1997). It is assumed that the 
Mi2 complex catalyses an ATP dependand mechanism of Nucleosome remodelling, which 
makes activated genes accessible on the chromosome. This complex, called Nucleosome 
Remodeling Deacetylase (NuRD) seems to play a central role in one previously unknown 
way of gene activation (Zhang et al., 1998). Due to the size of the protein (240 kDa), attempts 
were made to identify the epitope sequences and to produce a smaller protein for diagnostic 
purposes. Independently, Mi2 alpha and Mi2 beta were described in 1995 by Ge et al. (Ge et 
al., 1995) and Seelig et al. (Seelig et al., 1995) wich share a sequential homology of 68 % and 
have parts of high similarity (Seelig et al., 1996). Sera reacting with the natural form of the 
Mi2 autoantigen also react with the two different recombinant forms in a highly similar 
matter. First attempts to solve the three dimensional structure were made by Kwan et al. in 
2003 seen in figure 3 (Kwan et al., 2003). The structure of the complex was revealed only 
lately by Lejon et al. (Lejon et al., 2011a), as shown in figure 4. Mi2 can be easily produced 
recombinantly using the Baculovirus expression system (Hentschel et al., 2002; Schulte-
Pelkum, 2005). 
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Fig. 3. Chromodomain helicase-DNA-binding protein Mi2 subunit (Kwan et al., 2003). 
 
 
Fig. 4. The NURD complex (Lejon et al., 2011b). 
5. PM-Scl- and PM1 Alpha 
Although found in high frequency in patients with myositis, autoantibodies against the 
PM/Scl Antigen are rather myositis associated antibodies (maa) than myositis specific 
antibodies (msa) (Targoff, 2000). The main antigen, targeted by nearly all anti-PM/Scl 
positive sera is the PM/Scl 100 protein, which is part of a major protein complex of 11 
proteins. Many sera also react with a 75 kDa protein referred to as PM/Scl 75. This protein 
migrates with an apparent size of 75 kDa in SDS PAGE, but has a calculated size of about 40 
kDa, a phenomenon which can be explained by the highly charged carboxyterminal half of 
the protein. The other proteins of this complex are not targeted by autoantibodies associated 
with polymyositis. The biological function of the protein complex containing PM/Scl 100 
and PM/Scl 75 seems to be analogous to the exosome complex of yeast, in which RNA is 
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processed. Within this complex the degradation of RNA, the maturation of 5,8 S rRNA and 
the processing of small nuclear RNAs and AU-rich mRNAs (Raijmakers et al., 2003) is 
processed. Allmang et al. found out, that size and structure of the yeast exosome complex 
are the same as the PM/Scl complex in a human cell (Allmang et al., 1999). This complex can 
be found in the granular parts of the nucleoli and within the nucleoplasma. The PM/Scl 100 
protein is the analogue to the yeast Rrp6p-protein, the PM/Scl 75 protein the analogue to 
the Rrp4p- protein (Van Eenennaam et al., 2002). As there was no three dimensional 
structure available, Parker and Song published a theoretical structure showing a ring-like 
structure of the proteins of the exosome complex (Parker and Song, 2004), shown in  
figure 5.  
 
 
Fig. 5. The hypothetical exosome complex according to Parker et al. (Parker and Song, 2004). 
Brouwer et al. (Brouwer et al., 2002) described reactivities towards the exosome complex for 
patients with idiopathic inflammatory myopathies, overlap syndromes and scleroderma. 
These reactivities were only found in a combination with reactivity against PM/Scl 100. 
Initial use of the PM/Scl 100 antigen showed good sensitivity and specificity using a full 
length 100 kDa antigen (Hentschel et al., 2002). While a debate was going on whether the 
PM/Scl 75 or the PM/Scl 100 antigen should be used as the preferred antigen for IVD 
testing (Raijmakers et al., 2004; Mahler and Raijmakers, 2007a; Brouwer et al., 2002), a 
peptide sequence between amino acids 231 and 245 was found which could be proven as the 
main site of autoantibody binding in the PM/Scl autoantigen (Bluthner et al., 2000a; Mahler 
et al., 2003; Mahler and Raijmakers, 2007b). The major epitope of PM/Scl referred to as PM1 
alpha, consists of a local alpha helical structure. When an PM1 Alpha ELISA was recently 
compared to ELISA tests using the recombinant antigens with 75 and 100 kDa respectively, 
the best discrimination between preselected PM/Scl positive Sera (defined by Immunoblot, 
indirect immunofluorescence and Immunodiffusion) and control sera was observed with the 
PM1-Alpha ELISA with an area under the curve, AUC =1.0 compared to the PM/Scl-100 
(AUC = 0.98) and PM/Scl-75 ELISA (AUC = 0.85) as revealed by receiver operating 
characteristics (ROC) analysis. This observation shows an interesting aspect: due to the 
higher local density of the immunodominant sequence, a peptide can even be the better 
antigen than the protein sequence it was derived from.  
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6. Ku –DNA-PK 
Antibodies against the Ku-Complex can be found in 1-7 % of myositis patients and in 5 to 25 % 
of patients suffering from the polymyositis scleroderma overlap syndrome. The Ku 
autoantigen in its natural form is the regulatory subunit of the DNA phosphokinase complex 
(DNA-PK). This complex catalyses the non-homologous-end-joining (NHEJ), a repair 
mechanism for DNA double strand breaks. The complex consists of three subunits: Ku70, 
Ku80, and the much bigger catalysing subunit. If DNA-double strand breaks occur, e.g. due to 
ionizing radiation, the Ku-proteins form a dimer around the broken DNA and form a binding 
site for the 460 kDa catalysing subunit of the DNA-PK complex. The three units form the 
DNA-PK holoenzyme (Mimori, 1996; Dynan and Yoo, 1998; Wang et al., 1998). This complex 
also seems to play a central role in the genetic recombination of the different genetic 
subsequences of antibodies, facilitating the recombination of the different light and heavy 
chain- coding sequences (VDJ-joining). Here the 75-100 V-genes, the 10-20 D-genes and the 6 J-
genes are recombinated freely to form ~12000 different forms of heavy chain genes, which, 
combined with the 1000 different forms of light (L) chains form up to 107 to 108 different 
antibody specificities that form the human immune system. The recombination is catalyzed by 
enzyme complexes called RAG-1 and RAG-2, the ligation of the DNA strands by the DNA-PK-
complex containing the KU-proteins (Manis et al., 1998; Stryer et al., 2002). A defect in the 
catalytic or regulatory subunit of DNA-PK causes for the severe combined immunodeficiency 
syndrome as known from SCID-mice. The three dimensional structure of the Ku70/80-DNA 
binding mechanism was identified in 2001 by Walker et al. (Walker et al., 2001) and shows the 
spacial interaction of the two Ku-proteins, which, both binding the DNA, mate to form a 
complex structure, as shown in figure 6. The figure shows the two units in different colours to 
ease differentiation. The interdigitating structures of the two protein subunits can be clearly 
seen forming a complex structure surrounding the DNA. 
 
 
Fig. 6. Ku 70/80 Heterodimer, bound to a DNA molecule (Walker et al., 2001). 
The name Ku is derived from the initials of a myositis patient. Anti Ku70/80 antibodies 
were firstly described by Mimori et al. (Mimori et al., 1981) in a Japanese patient suffering 
from the polymyositis/scleroderma overlap syndrome. Even in this early stage it was 
shown, that sometimes autoantibodies against only one of the subunits, but sometimes 
autoantibodies against both subunits occurred. Antibodies were also detectable against the 
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whole complex of both regulatory subunits and the catalyzing subunit of DNA-PK. This so 
called particle antigen was assembled from highly purified native components. Antibodies 
were found against subunits but also against three dimensional structures of the complete 
particle antigen (Jafri et al., 2001). The question which one of the two subunits of the Ku 
antigen offers the higher sensitivity and specificity for myositis diagnosis was raised and 
Wang et al. (Wang et al., 1997) published a study with showed that about 50 % of the 
patients showed reactivity against both subunits, 30 % reacted only with the 80 kDa subunit 
whereas only 3 % showed exclusive reactivity against the 70 kDa Subunit alone. Also of 
interest in this study was the observation that 18 % of the screened myositis patients had no 
reactivity against the one or the other subunit, but instead showed antibodies against the 
heterodimeric form of Ku70/80. For diagnostic purposes a native form of the heterodimeric 
Ku70/80 complex is the antigen of choice. Experiments showed a far better discrimination 
using the heterodimeric naitve antigen compared to separately purified subunits, which 
later were co-coated on an ELISA plate (Schulte-Pelkum, 2005) 
7. SRP –Signal recognition particle 
Anti Signal recognition particle (SRP, SRP 54) antibodies are rare autoantibodies in myositis 
with a prevalence of only 5 %, but the anti SRP reactivity coincides with a severe onset of 
polymyositis (Targoff et al., 1990). Normal corticosteroid treatment usually shows no 
positive effect on the disease progress on aSRP 54 pos patients. Newer data as described by 
Hengstman (Hengstman et al., 2006), after conducting an international study with 23 aSRP 
positive patient samples found anti SRP 54 reactivity as a marker for a necrotising myopathy 
rather than a classical myositis. The patients symptoms differed only in some cases from the 
symptoms of the anti-SRP negative myositis control group, but anti SRP pos patients 
suffered significantly more often from dysphagia and muscle atropy. Also the biopsy 
samples differed significantly, as there were no myositis specific histological features like 
inflammatory infiltrates, making anti SRP antibody positive patients a distinct group next to 
the more classical myositis. Firstly described as an autoantibody by Reeves et al. (Reeves et 
al., 1986), the SRP is the primary tool for the targeting of the nascent polypeptide chain. 
proteins which have to be folded and/or glycosylated within the endoplasmatic reticulum 
have to have a signal peptide sequence on the aminoterminus. The exact structure of this 
signal sequence seems to be of lesser importance, although all signal-sequences contain 
repeating motives of hydrophobic aminoacids alternating with serine and threonine 
residues, which can be found in many different signal sequences moderating the protein 
targeting. The complex which catalyzes the targeting of the de-novo sequences is the SRP. 
This complex contains the 7SL-RNA and six proteins of 9, 14, 19, 54, 68 and 72 kDa. The SRP 
54 kDa is the protein which directly binds to the signal sequence of the nascent protein. The 
complex containing ribosome, nascent protein and SRP then binds to the SRP-receptor and 
to a translocon, a protein on the outside of the rough ER, which then forms a channel inside 
the ER-lumen. Inside the ER the signal sequence is cleaved by a signal peptidase, while the 
rest of the protein is now synthesized directly into the lumen of the ER. The three 
dimensional structure of SRP 54 as shown in figure 7, was determined by Gowda et al. 
(Gowda et al., 1998; Gowda et al., 1999). The epitopes of SRP 54 showed to be structural 
epitopes, which is easily understood looking at the structure of the protein, consisting nearly 
only from Helix-turn-Helix motives. Interestingly Beneviste et al. observed that the aSRP54 
antibody titer in a cohort of 8 longitudinally followed patients correlated (Benveniste et al., 
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2011) to a high degree with disease activity as measured e.g. by serum creatine kinase 
activity.  
 
 
Fig. 7. Structure of SRP 54 (Gowda et al., 1998). 
8. CADM140 / MDA 5  
Newly shown by Nakashima (Nakashima et al., 2010) the antibody firstly described as a-
CADM140 autoantibody recognises the melanoma differentiation-associated Gene 5 protein 
(MDA 5) which plays a role in innate immune responses. Patients with this reactivity suffer 
from clinically amyopathic Dermatomyositis (CADM) and have a high risk for life-
threatening complications in DM, namely due to the rapidly progressing interstitial lung 
involvement. After the antibodies were first reported in Japan with a prevalence of around 
25 % in DM cohorts (Hoshino et al., 2010), retrospective testing of dermatomyositis groups 
revealed also in Europe that up to 13 % of DM patients have antibodies against MDA 5, with 
a clear correlation for severe forms of rapidly progressing ILD and poor prognosis (Labirua 
and Lundberg, 2010; Fiorentino et al., 2011). 
9. TIF1 gamma  
First described as the anti P155 antibody the antigen bound by this antibody was revealed to 
be the TIF1 gamma protein of the tripartite motive family (TRIM 33) like other autoantigens, 
a zinc finger protein (Targoff et al., 2006a). It is (at the moment) thought to be a 
transcriptional corepressor. It was described first by Targoff et al. (Targoff et al., 2006b). The 
clinical manifestations of this reactivity involve high prevalences in dermatomyositis, as 
reported by Targoff et al., but with a high specificity the occurrence of this MSA correlates 
with a risk of malignancies as (Kaji et al., 2007). This observation was statistically underlined 
when Selva O´Canaghan et al. performed a meta analysis for anti TIF 1 gamma antibodies 
and predictive values for malignancies (Selva-O'Callaghan et al., 2010) and found that anti 
p155/TIF1 y antibodies have a 70 % sensitivity and a 90 % specificity to detect occult 
malignancies in DM. The TIF1 gamma protein as described by Venturini et al. shows a 
strong silencing activity towards gentic promoter sequences. In this promoter sequences, 
binding affinity of TIF1 gamma is dependant of a single motive (Venturini et al., 1999). 
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10. U1-snRNP  
Antibodies against the U1-RNP complex are, like anti-Ku and anti-PM/Scl antibodies MAA. 
An association with PM can be found in 4-17 % of myositis cases, whereas these 
autoantibodies have a prevalence of 100 % in mixed connective tissue disease (MCTD). 
Absence of this antibodies rules out the diagnosis of MCTD (Conrad et al., 2001a). The U1 
RNP consists of three small nuclear ribonuclear proteins (snRNP-“SNURPS”) A (34 kDa); C 
(22 kDa) and the 68 kDa protein. Most prominent is reactivity against the 68 kDa protein. 
Considering this reactivity the coincidence of an autoimmune disease and a cytomegalo 
virus infection was discussed (Newkirk et al., 2001), after high rates of coinciding SLE after 
CMV infections were reported (Newkirk et al., 2001). The U1-snRNP complex belongs to the 
snRNP protein and is involved in the splicing process of the pre-messenger RNA. In 
mammalian cells the U1-snRNP binds the 5´splicing site of an intron with a 15 nucleotide 
consensus sequence of its 165 base long snRNA sequence; the subunits of the U1-RNP then 
bind to this snRNA. Not all proteins bind directly to the snRNA, RNP-C for example binds 
with a zinc finger motive to the complex of RNA and the other RNP-proteins (Nelissen et 
al., 1991). The sequences were published by Sillekens et al (U1-RNP-A), Yamamoto et al. 
(U1-RNP-C) and by Theissen et al. (U1-RNP-68) (Sillekens et al., 1987; Yamamoto et al., 
1988; Theissen et al., 1986). Figure 8 shows the structure of U1-RNP-A bound to RNA 
(Varani et al., 2000). A scheme of the complete U1 RNP is shown in Figure 9.  
11. Ro52  
Although Ro52 and Ro60 (SS-A), shown early to be separate proteins (Chan et al., 1991), 
were initially suggested to be closely related, no direct interaction of the proteins could be 
conclusively shown. Recent studies indicated that the proteins are even localized in different 
cell compartments and they perform rather different functions. The 52 kDa Ro antigen was 
eventually identified as tripartite motif protein (TRIM) 21 ubiquitin-ligase that is over-
expressed in peripheral blood mononuclear cells in SjS and SLE patients (Rhodes et al., 2002; 
Wada and Kamitani, 2006). Ro52 is reported to interact with several different molecules, 
among them calreticulin and a 78 kDa glucose-regulated protein (GRP78), also known as 
immunoglobulin heavy chain-binding protein (BIP) and formerly proposed as an early 
marker for rheumatoid arthritis (Blass et al., 2001). Taking its function into consideration, 
Ro52 is thought to modify the role or stability of its substrates through ubiquitination, and 
this modification might result in the Ro52-mediated biological events (Wada and Kamitani, 
2006; Gomez-Martin et al., 2008).  
12. Association between anti-Ro52 and anti-Ro60 antibodies in different 
autoimmune diseases 
Testing for SS-A/Ro60 and Ro52 with sera from SSA/Ro related autoimmune diseases 
showed differing prevalences of the two autoantibodies in the different disease entities 
(see Figure 10). The frequencies of anti-Ro52 antibodies and anti-Ro60 were comparable in 
all groups except the myositis and scleroderma cohort. The prevalences of anti-Ro52 
reactivitiy without anti-Ro60 reactivity varied in the different groups from 14.5 % in SLE 
to 37.5 % in the myositis group. In the SjS group, 51.7 % of anti-Ro52 sera had also 
antibodies to Ro60. 
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Fig. 8. U1 RNP–A bound to RNA (grey) (Varani et al., 2000). 
 
 
Fig. 9. Schematic view of the snRNP. 
 
 
Fig. 10. Anti Ro antibody profiles in different disease groups (Schulte-Pelkum et al., 2008). 
www.intechopen.com
 Serological Aspects of Myositis 
 
37 
13. Coincidence of anti-Ro52 and anti-Jo-1 in patients with polymyositis 
A high degree of correlation was found in a group of myositis sera tested for aab against Jo-
1 and Ro52: a panel of 43 sera of myositis patients revealed reactivities against Ro52 and Jo-1 
in 70 % (p=0.0002, Odds ratio=14.17, kappa=0.54) of Jo-1 positive sera when tested with 
ELISA (Dr. Fooke Laboratorien) and ALBIA. 22 (24) sera were found positive for anti-Jo-1 by 
ELISA and ALBIA (numbers in brackets), 16 (17) of these were also found positive for anti-
Ro52 (72 % by ELISA, 70.8 % by ALBIA). These observations underline previous conclusions 
(Peene et al., 2002) that anti-Ro52 is indeed an independent aab in myositis. Rutjes et al. 
(Rutjes et al., 1997) found anti-Ro52 reactivity in 58 % of Jo-1 positive myositis sera, an 
observation confirmed in the subsequent years by Rozman et al. (2000), Brouwer et al. (2001) 
and Koenig et al. (2007) (Rozman et al., 2000; Brouwer et al., 2001; Koenig et al., 2007). In 
contrast, Langguth et al. (Langguth et al., 2007) indicated that isolated anti-Ro52 reactivity 
has limited clinical value in a non-obstetric population, a conclusion that could not be 
confirmed. Our study demonstrated the importance of detecting anti-Ro52 and anti-Ro60 
aab separately when considering the diagnosis of patients and in particular myositis 
patients. This perspective was not included in the study performed by Langguth and 
colleagues.  
It can be concluded that anti-Ro52 clearly differs in reactivity from anti-Ro60 (SS-A): Anti-
Ro52 is seen in relatively high frequency in myositis and SSc. Anti-Ro52 has a prevalence of 
up to 35 % in myositis and in this disease group co-occurs in up to 72 % of anti-Jo-1 positive 
sera. In our opinion it is strongly recommend that diagnostic assays and kits should test 
anti-Ro52 and anti-Ro60 (SS-A) separately (Schulte-Pelkum et al., 2008; Schulte-Pelkum et 
al., 2009).  
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